Mark DeLong - Jul 19, 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Senior Vice President
Signature
/s/ David Watson, attorney-in-fact for Mark Delong
Stock symbol
APLS
Transactions as of
Jul 19, 2022
Transactions value $
-$204,500
Form type
4
Date filed
7/21/2022, 04:31 PM
Previous filing
Jun 21, 2022
Next filing
Jul 28, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $77.6K +5K +17.09% $15.52 34.3K Jul 19, 2022 Direct F1
transaction APLS Common Stock Sale -$282K -5K -14.6% $56.42 29.3K Jul 19, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -5K -14.29% $0.00 30K Jul 19, 2022 Common Stock 5K $15.52 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This is a scheduled exercise and sale from an established 10B5-1 trading plan.
F2 This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant date, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.